Last 47 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
STRATA Skin Sciences, Inc.'s quarterly P/E stands at 32.1x.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.10 | 32.14 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.03 | 0.20 | 3.33 | 3.12 | 4.04 | 2.89 | 3.16 | 3.19 | 4.91 | 5.54 | 5.87 | 10.04 | 12.20 |
| — | -93.1% | +5.5% | -2.3% | -17.6% | -47.8% | -46.2% | -68.2% | -59.8% | -14.3% | -27.0% | +9.6% | -32.6% | |
| P/B Ratio | 2.19 | 2.55 | 70.25 | 310.13 | 41.26 | 22.28 | 11.89 | 11.33 | 14.05 | 15.18 | 12.83 | 19.60 | 19.11 |
| — | -88.6% | +491.0% | +2636.1% | +193.6% | +46.8% | -7.3% | -42.2% | -26.5% | +20.8% | -7.5% | +31.2% | -10.9% | |
| P/FCF | — | — | — | — | — | 139.18 | — | 109.39 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 4.18 | — | — | — | — | — | 35.19 | — | — | 58.59 | — | — |
| — | — | — | — | — | — | — | — | — | — | -54.3% | — | — | |
| EV / EBIT | — | 106.59 | — | — | — | — | — | 68.67 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
STRATA Skin Sciences, Inc.'s operating margin was 0.4% in Q4 2025, up 27.2 pp QoQ and up 44.5 pp YoY. This marks the 5th consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -21.3% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 58.3% | 60.4% | 60.4% | 56.2% | 53.5% | 60.1% | 60.3% | 58.5% | 45.6% | 55.3% | 56.0% | 52.3% | 58.0% |
| — | +0.5% | +0.1% | -4.0% | +17.4% | +8.8% | +7.8% | +11.8% | -21.4% | -14.5% | -9.2% | -4.6% | -1.1% | |
| Operating Margin | -19.0% | 0.4% | -26.8% | -29.0% | -29.6% | -44.1% | -18.8% | -5.8% | -42.8% | -39.6% | -6.9% | -23.8% | -34.2% |
| — | +100.9% | -42.6% | -403.7% | +30.8% | -11.5% | -170.5% | +75.8% | -25.2% | -3233.3% | +16.8% | -27.8% | -4.5% | |
| Net Margin | -20.4% | 0.6% | -23.4% | -32.5% | -35.7% | -47.0% | -24.1% | -1.2% | -49.9% | -43.7% | -11.9% | -38.2% | -37.5% |
| — | +101.3% | +3.0% | -2667.4% | +28.4% | -7.6% | -102.8% | +96.9% | -33.1% | -2793.4% | -12.5% | -83.6% | -5.4% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -158.9% | 2.7% | -200.0% | -167.2% | -63.7% | -62.8% | -22.5% | -1.0% | -30.5% | -26.3% | -6.4% | -17.4% | -13.8% |
| — | +104.4% | -787.8% | -15884.6% | -109.0% | -139.1% | -254.1% | +94.0% | -121.0% | -3482.4% | -41.1% | -111.8% | -35.5% | |
| ROA | -18.8% | 0.2% | -5.3% | -7.7% | -6.9% | -11.8% | -5.3% | -0.2% | -8.2% | -8.5% | -2.1% | -6.0% | -5.6% |
| — | +101.6% | +0.7% | -2980.1% | +15.9% | -38.5% | -158.6% | +95.9% | -46.8% | -2704.5% | -10.4% | -73.3% | -13.6% | |
| ROIC | -34.4% | 0.3% | -13.1% | -14.3% | -11.3% | -19.3% | -6.3% | -1.8% | -10.3% | -11.1% | -1.9% | -6.1% | -7.8% |
| — | +101.3% | -107.7% | -712.1% | -10.4% | -72.8% | -231.2% | +70.9% | -31.4% | -2736.6% | +30.6% | +2.0% | +5.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
STRATA Skin Sciences, Inc.'s Debt/EBITDA ratio is 17.3x — elevated, raising questions about debt serviceability. The current ratio has weakened 48.6% YoY to 0.58x, tightening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 5.59 | 5.59 | 12.41 | 53.09 | 6.14 | 3.31 | 1.76 | 1.74 | 1.75 | 1.23 | 0.97 | 0.93 | 0.43 |
| — | +69.2% | +603.9% | +2953.8% | +250.3% | +168.3% | +81.9% | +86.5% | +304.0% | +218.7% | +153.0% | +163.4% | +29.5% | |
| Debt / EBITDA | — | 17.25 | — | — | — | — | — | 19.58 | — | — | 17.01 | — | — |
| — | — | — | — | — | — | — | — | — | — | +20.5% | — | — | |
| Current Ratio | 0.58 | 0.58 | 0.95 | 0.98 | 1.05 | 1.13 | 1.13 | 1.14 | 1.05 | 1.28 | 1.64 | 1.50 | 1.11 |
| — | -48.6% | -16.0% | -13.7% | -0.3% | -11.1% | -31.1% | -24.3% | -5.4% | -2.1% | +23.8% | +16.0% | -15.9% | |
| Quick Ratio | 0.48 | 0.48 | 0.75 | 0.75 | 0.87 | 0.98 | 0.94 | 0.92 | 0.84 | 1.06 | 1.13 | 1.09 | 0.68 |
| — | -51.3% | -20.2% | -18.0% | +4.2% | -7.2% | -17.3% | -15.5% | +24.1% | +18.7% | +22.3% | +13.6% | -31.9% | |
| Interest Coverage | -2.98 | 0.08 | -2.26 | -4.07 | -4.00 | -8.06 | -2.95 | 0.81 | -5.43 | -2.19 | -0.99 | -9.56 | -8.91 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SSKN stock.
STRATA Skin Sciences, Inc.'s current P/E is -0.1x. The average P/E over the last 1 quarters is 32.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
STRATA Skin Sciences, Inc.'s current operating margin is -19.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking STRATA Skin Sciences, Inc.'s business trajectory between earnings reports.